Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H3O2.H4N |
Molecular Weight | 77.0825 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[NH4+].CC([O-])=O
InChI
InChIKey=USFZMSVCRYTOJT-UHFFFAOYSA-N
InChI=1S/C2H4O2.H3N/c1-2(3)4;/h1H3,(H,3,4);1H3
Molecular Formula | C2H4O2 |
Molecular Weight | 60.052 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H3N |
Molecular Weight | 17.0305 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39de0239-a4f6-45b0-a3cf-c6fba941c08ehttp://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022041s008s009lbl.pdfCurator's Comment: description was created based on several sources, including
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39de0239-a4f6-45b0-a3cf-c6fba941c08ehttp://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022041s008s009lbl.pdf
Curator's Comment: description was created based on several sources, including
Hydroxocobalamin (also hydroxycobalamin, OHCbl) is a natural form, or vitamer, of vitamin B12. It is a member of the cobalamin family of compounds. Hydroxocobalamin, the active ingredient in Cyanokit, is cobinamide dihydroxide dihydrogen phosphate (ester), mono (inner salt), 3’-ester with 5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole. The drug substance is the hydroxylated active form of vitamin B12 and is a large molecule in which a trivalent cobalt ion is coordinated in four positions by a tetrapyrol (or corrin) ring. It is a hygroscopic, odorless, dark red, crystalline powder that is freely soluble in water and ethanol, and practically insoluble in acetone and diethyl ether. Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. Cyanide is an extremely toxic poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular hypoxia and metabolic acidosis. In massive acute cyanide poisoning, the mechanism of toxicity may involve other enzyme systems as well. Signs and symptoms of acute systemic cyanide poisoning may develop rapidly within minutes, depending on the route and extent of cyanide exposure. The action of Cyanokit is based on its ability to bind cyanide ions. Each hydroxocobalamin molecule can bind one cyanide ion by substituting it for the hydroxo ligand linked to the trivalent cobalt ion, to form cyanocobalamin, which is then excreted in the urine.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2117062https://www.ncbi.nlm.nih.gov/pubmed/14668053
Curator's Comment: Acetic acid was shown to cross the blood brain barrier in rats.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: cyanide ions |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CYANOKIT Approved UseCyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. (1.1) If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. (1.2) The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. (1.2) 1.1 Indication Cyanokit is indicated for the treatment of known or suspected cyanide poisoning. 1.2 Identifying Patients with Cyanide Poisoning Cyanide poisoning may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide poisoning include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside. The presence and extent of cyanide poisoning are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. Table 1 Common Signs and Symptoms of Cyanide Poisoning Symptoms Signs Headache Altered Mental Status (e.g., confusion,disorientation) Confusion Seizures or Coma Dyspnea Mydriasis Chest tightness Tachypnea / Hyperpnea (early) Nausea Bradypnea / Apnea (late) Hypertension (early) / Hypotension (late) Cardiovascular collapse Vomiting Plasma lactate concentration ≥ 8 mmol/L In some settings, panic symptoms including tachypnea and vomiting may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of true cyanide poisoning although these signs can occur with other toxic exposures as well. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. Smoke Inhalation Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances making a diagnosis of cyanide poisoning particularly difficult. Prior to administration of Cyanokit, smoke-inhalation victims should be assessed for the following: Exposure to fire or smoke in an enclosed area Presence of soot around the mouth, nose or oropharynx Altered mental status Although hypotension is highly suggestive of cyanide poisoning, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide poisoning is a plasma lactate concentration ≥ 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide poisoning because carbon monoxide associated with smoke inhalation also contributes to lactic acidemia). If cyanide poisoning is suspected, treatment should not be delayed to obtain a plasma lactate concentration. 1.3 Use with Other Cyanide Antidotes Caution should be exercised when administering other cyanide antidotes simultaneously with Cyanokit, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote with Cyanokit, these drugs should not be administered concurrently in the same intravenous line. [see Dosage and Administration (2.3) Launch Date2006 |
|||
Curative | VOSOL Approved UseFor the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial. Launch Date1960 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4511.6 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8699553 |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXOCOBALAMIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8699553 |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXOCOBALAMIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 1 times / day multiple, intramuscular Dose: 20 mg, 1 times / day Route: intramuscular Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 13 years n = 1 Health Status: unhealthy Age Group: 13 years Sex: M Population Size: 1 Sources: |
|
20 g single, intravenous Highest studied dose Dose: 20 g Route: intravenous Route: single Dose: 20 g Sources: |
unhealthy, 26.9 years n = 1 Health Status: unhealthy Age Group: 26.9 years Sex: M Population Size: 1 Sources: |
|
5 g single, intravenous Overdose |
unhealthy, 3 years n = 1 Health Status: unhealthy Condition: cyanide toxicity Age Group: 3 years Sex: F Population Size: 1 Sources: |
|
5 g single, intravenous |
unhealthy, 62 years n = 1 Health Status: unhealthy Condition: Vasoplegic Syndrome Age Group: 62 years Sex: M Population Size: 1 Sources: |
|
2000 ug 2 times / day multiple, oral Dose: 2000 ug, 2 times / day Route: oral Route: multiple Dose: 2000 ug, 2 times / day Sources: |
unhealthy, adult n = 8 Health Status: unhealthy Condition: pernicious anaemia Age Group: adult Population Size: 8 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway. | 2000 |
|
Antinociceptive properties of the methanolic extract and two triterpenes isolated from Epidendrum Mosenii stems (Orchidaceae). | 2000 Jan 21 |
|
Treatment of gastric ulcers and diarrhea with the Amazonian herbal medicine sangre de grado. | 2000 Jul |
|
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor. | 2000 Jul |
|
Antinociceptive properties of extracts of new species of plants of the genus Phyllanthus (Euphorbiaceae). | 2000 Sep |
|
Subcellular localization of Rab17 by cryo-immunogold electron microscopy in epithelial cells grown on polycarbonate filters. | 2001 |
|
Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring. | 2001 Feb |
|
In vivo (13)C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during. | 2001 Feb |
|
Analgesic and anti-inflammatory effects of Mangifera indica L. extract (Vimang). | 2001 Feb |
|
Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy. | 2001 Feb |
|
In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data. | 2001 Feb |
|
Structure of manganese diacetate tetrahydrate and low-temperature methyl-group dynamics. | 2001 Feb |
|
Biodistribution of radiolabeled [(3)H] CMT-3 in rats. | 2001 Feb |
|
Lipase-catalyzed irreversible transesterification of 1-(2-furyl)ethanol using isopropenyl acetate. | 2001 Feb |
|
Effect of acetate on glycogen replenishment in liver and skeletal muscles after exhaustive swimming in rats. | 2001 Feb |
|
Screening for cervical neoplasia in a developing country utilizing cytology, cervicography and the acetic acid test. | 2001 Feb |
|
Biochemical study of collagen in adult groin hernias. | 2001 Feb |
|
Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. | 2001 Feb |
|
Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. | 2001 Feb |
|
Videographic assessment of the embolic characteristics of three polymeric compounds: ethylene vinyl alcohol, cellulose acetate, and liquid urethane. | 2001 Feb |
|
Asymmetric synthesis and preliminary evaluation of (R)- and (S)-[11C]bisoprolol, a putative beta1-selective adrenoceptor radioligand. | 2001 Feb |
|
Physiological responses to mixing in large scale bioreactors. | 2001 Feb 13 |
|
Increased affinity of c-Myb for CREB-binding protein (CBP) after CBP-induced acetylation. | 2001 Feb 2 |
|
Construction of acetate auxotrophs of Neisseria meningitidis to study host-meningococcal endotoxin interactions. | 2001 Feb 23 |
|
Protein kinase C phosphorylates RGS2 and modulates its capacity for negative regulation of Galpha 11 signaling. | 2001 Feb 23 |
|
Computational studies on nonenzymatic and enzymatic pyridoxal phosphate catalyzed decarboxylations of 2-aminoisobutyrate. | 2001 Feb 6 |
|
Clostridium hungatei sp. nov., a mesophilic, N2-fixing cellulolytic bacterium isolated from soil. | 2001 Jan |
|
Expression of alpha-amylase gene in rat liver: liver-specific amylase has a high affinity to glycogen. | 2001 Jan |
|
Acetylcholinesterase assay for rapid expression screening in liquid and solid media. | 2001 Jan |
|
The metal binding properties of the CCCH motif of the 50S ribosomal protein L36 from Thermus thermophilus. | 2001 Jan |
|
Purification and characterization of a cellulase from the ruminal fungus Orpinomyces joyonii cloned in Escherichia coli. | 2001 Jan |
|
Peripheral and preemptive opioid antinociception in a mouse visceral pain model. | 2001 Jan |
|
Precursor supply for polyketide biosynthesis: the role of crotonyl-CoA reductase. | 2001 Jan |
|
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. | 2001 Jan |
|
Iron-induced changes in pyruvate metabolism of Tritrichomonas foetus and involvement of iron in expression of hydrogenosomal proteins. | 2001 Jan |
|
Molecular characterization and diversity of thermophilic iron-reducing enrichment cultures from deep subsurface environments. | 2001 Jan |
|
Role of botrytized grape micro-organisms in SO2 binding phenomena. | 2001 Jan |
|
Early assessment of regional myocardial blood flow and metabolism in thrombolysis in myocardial infarction flow grade 3 reperfused myocardial infarction using carbon-11-acetate. | 2001 Jan |
|
Differential effects of lead and zinc on inhibitory avoidance learning in mice. | 2001 Jan |
|
Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. | 2001 Jan |
|
Non-synaptic transformation of gustatory receptor potential by stimulation of the parasympathetic fiber of the frog glossopharyngeal nerve. | 2001 Jan |
|
Studies of the structure of insulin fibrils by Fourier transform infrared (FTIR) spectroscopy and electron microscopy. | 2001 Jan |
|
Modelling the influence of pH and organic acid types on thermal inactivation of Bacillus cereus spores. | 2001 Jan 22 |
|
Optimised determination of clobazam in human plasma with extraction and high-performance liquid chromatography analysis. | 2001 Jan 5 |
|
p300 does not require its acetylase activity to stimulate p73 function. | 2001 Jan 5 |
|
Evaluation of a novel vitamin E coated cellulosic membrane hollow fiber dialyzer. | 2001 Jan-Feb |
|
Salt accumulation resulting from base added for pH control, and not ethanol, limits growth of Thermoanaerobacteriumthermosaccharolyticum HG-8 at elevated feed xylose concentrations in continuous culture. | 2001 Jan-Feb |
|
Acute and chronic toxicity of Potassium Chloride (KCl) and Potassium Acetate (KC(2)H(3)O(2)) to Daphnia similis and Ceriodaphnia dubia (Crustacea; Cladocera). | 2001 Mar |
|
Measurement of low picomolar levels of triamcinolone acetonide in human bronchoalveolar lavage fluid by gas chromatography-electron-capture negative-ion mass spectrometry. | 2001 Mar 1 |
|
Characterization of bioreaction processes: aerobic Escherichia coli cultures. | 2001 Nov 30 |
Patents
Sample Use Guides
To promote continuous contact, insert a wick of cotton saturated with the drug solution (Vosol). Keep the wick in for at least 24 hours and keep it moist by adding 3 to 5 drops of solution every 4 to 6 hours. The wick may be removed after 24 hours but the patient should continue to instill 5 drops of the drug solution 3 or 4 times daily thereafter, for as long as indicated.
Route of Administration:
Otic (auricular)
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11420658
Curator's Comment: Hydroxocobalamin (OH-Cbl), when used to treat vitamin B12 deficiency, is better retained by the body than is cyanocobalamin (CN-Cbl), but the availability to cells has not been studied systematically. In a series of experiments, were compared the uptake and internalization of OH-Cbl and CN-Cbl bound to transcobalamin II (TCII) by a human cell model, the HeLa cell. TCII-OH-Cbl was: (1) taken up in larger amounts per unit time, (2) the greater uptake was not a consequence of more effective attachment to receptors of TCII-Cbl nor to a more rapid regeneration of receptors, (3) the difference was expressed during the phase of internalization of TCII-Cbl, (4) with CN-Cbl, the stages of binding to receptors plus internalization were more readily reversed, and (5) larger amounts of OH-Cbl were internalized and converted to active coenzyme forms of Cbl.
Acetic acid inhibited Saccharomyces cerevisiae growth. The minimum inhibitory concentration (MIC) of acetic acid for yeast growth was 0.6% w/v (100 mM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:15:02 GMT 2023
by
admin
on
Fri Dec 15 15:15:02 GMT 2023
|
Record UNII |
RRE756S6Q2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
631-61-8
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
211-162-9
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
62947
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
100000088037
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
1362883
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID5023873
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
RRE756S6Q2
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
RRE756S6Q2
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
C45678
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
C77452
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
12432
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
SUB12869MIG
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
556
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
C018824
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | |||
|
m1762
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY | Merck Index | ||
|
AMMONIUM ACETATE
Created by
admin on Fri Dec 15 15:15:02 GMT 2023 , Edited by admin on Fri Dec 15 15:15:02 GMT 2023
|
PRIMARY |